Unjoni Ewropea - Malti - EMA (European Medicines Agency)

dechra regulatory b.v. - meloxicam - musculo-skeletal system, anti-inflammatory and anti-rheumatic products, non-steroids - dogs; cats - catsalleviation ta ' l-infjammazzjoni u l-uġigħ fil kronika disturbi muskolu-skeletrali. dogsalleviation mill-infjammazzjoni u uġigħ akut kif ukoll kroniku disturbi muskolu-skeletrali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - firocoxib - anti-inflammatory and anti-rheumatic products, non-steroids - klieb - tabletsfor-serħan mill-uġigħ u l-infjammazzjoni assoċjati ma ' l-ostjoartrite fil-klieb. għall-eżenzjoni ta 'uġigħ u infjammazzjoni wara l-operazzjoni assoċjati ma' tessut artab, kirurġija ortopedika u dentali fil-klieb. orali pastealleviation ta 'l-uġigħ u l-infjammazzjoni assoċjati ma' l-ostjoartrite u għat-tnaqqis tat-tizpip assoċjat fiż-żwiemel.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, tromboċitopenika, idjopatika - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 u 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 u 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

dr. falk pharma gmbh - budesonide - mard esophageal - antidiarrheals, intestinali anti-infjammatorji / antiinfective aġenti - jorveza huwa indikat għall-kura ta 'esofaġite eosinophilic (eoe) f'adulti (ta' età akbar minn 18-il sena).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - fasenra huwa indikat bħala żieda fit-trattament ta 'manteniment f'pazjenti adulti bi ħsara severa eżinofilika-ażma mhux ikkontrollati adegwatament, minkejja doża għolja ta' kortikosterojdi meħuda man-nifs biż-żieda fit-tul li jaġixxu β-agonisti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva pharma b.v.  - budesonide, formoterol fumarate dihydrate - asthma; pulmonary disease, chronic obstructive - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - budesonide / formoterol teva pharma b. hija indikata fl-adulti ta '18-il sena u akbar biss. asthmabudesonide/formoterol teva pharma b. huwa indikat fit-trattament regolari ta ' l-ażżma, fejn l-użu tal-kombinazzjoni (kortikosterojdi meħuda man-nifs u li jaħdem fit-tul β2 adrenoceptor agonist) huwa xieraq:-f'pazjenti li mhumiex adegwatament ikkontrollati bil-kortikosterojdi meħuda man-nifs u l - "kif meħtieġ" man-nifs qasir waqt li jaġixxi β2 adrenoceptor agonisti. jew f'pazjenti li diġà ikkontrollati adegwatament fuq iż-żewġ kortikosterojdi meħuda man-nifs u li jaħdem fit-tul β2 adrenoceptor agonisti. copdsymptomatic-trattament ta ' pazjenti b'copd mal-nifs sfurzat'il-volum fl-1 sekonda (fev1) .

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer animal health gmbh - florfenicol, terbinafine hydrochloride, mometasone furoate - otologicals, kortikosterojdi u antiinfectives flimkien - klieb - għat-trattament ta 'klieb otite esterna jew l-aggravament akut ta' otite rikurrenti kkawżati minn infezzjonijiet imħalta tal suxxettibbli razez ta ' batterji sensittivi għall-florfenicol (staphylococcus pseudintermedius) u fungi sensittivi għall-terbinafine (malassezia pakidermatite).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunosoppressanti - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - everolimus - carcinoma, renal cell; breast neoplasms; pancreatic neoplasms - aġenti antineoplastiċi - l-ormon tat-riċettur pożittiva tas-sider avvanzat cancerafinitor huwa indikat għall-kura ta 'l-ormon tat-riċettur-pożittivi, her2/neu negattivi għall-kanċer tas-sider avvanzat, f'kombinazzjoni ma exemestane, fil-nisa wara l-menopawsa mingħajr sintomatika vixxerali-marda wara l-rikorrenza jew l-progressjoni wara mediċini mhux sterojdi ta' inibitur aromatase. newroendokrinika tumuri tal-frixa originafinitor huwa indikat għall-kura ta li ma jistgħax jitneħħa kirurġikament, jew li mmetastatizza, sew jew moderatament differenzjati newroendokrinika tumuri tal-frixa-oriġini fl-adulti bil-marda progressiva. newroendokrinika tumuri tal-gastro-intestinali jew tal-pulmun originafinitor huwa indikat għall-kura ta li ma jistgħax jitneħħa kirurġikament, jew li mmetastatizza, differenzjat tajjeb (grad 1 jew ta ' grad 2) mhux funzjonali newroendokrinika tumuri tal-gastro-intestinali jew tal-pulmun-oriġini fl-adulti bil-marda progressiva. renali taċ-ċelluli carcinomaafinitor huwa indikat għall-kura ta ' pazjenti b'indeboliment avanzat tal-karċinoma taċ-ċellola, li l-marda tagħhom mexa fuq jew wara l-kura bil-vegf-terapija fil-mira.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

virbac s.a. - gentamicin sulfate, hydrocortisone aceponate, miconazole nitrate - otologicals, kortikosterojdi u antiinfectives flimkien - klieb - trattament ta 'otite esterna akuta u taħrix akut ta' otite esterna rikorrenti assoċjata ma ' bakterja suxxettibbli għal ġentamiċin u fungi suxxettibbli għal mikonażol, b'mod partikulari malassezia pachydermatis.